PYXS
Pyxis Oncology, Inc.
Next earnings Aug 12, 2026 (after close) · consensus $-0.36 EPS, $29.8K rev
Last earnings -15.6% on 2026-05-14
$2.23
▲ +2.77%$2.23▲ +90.60%
over 1Y
L $1.04EODHDH $5.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.8%
1W+9.9%
1M+36.8%
3M+60.4%
YTD+93.9%
1Y+90.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.71x); but revenue fell -14.2% YoY.
Pyxis Oncology, Inc. shows $13.9M in FY2025 revenue (-14.2% YoY), a -574.5% net margin, and -149.1% ROE.
Sources: SEC EDGAR (CIK 0001782223, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 12:46:03 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.